IL10RA is expressed in ALCL in an NPM1-ALK–independent manner. (A) Representative hematoxylin and eosin (H&E) staining with corresponding IL-10RA immunohistochemistry staining performed on TMAs from different human T-cell lymphoma subtypes: ALK⁺ and ALK⁻ ALCL, AITL, and PTCL-NOS. (B) Intensity of staining (left panels) or percentage of tumor cells expressing IL-10RA (upper right panel) or IL-10RB (lower right panel), as determined by immunohistochemistry of a TMA of formalin-fixed paraffin-embedded (FFPE) T-cell lymphoma patient samples: ALK⁺ ALCL, n = 25; ALK⁻ ALCL, n = 25; AITL, n = 7; PTCL-NOS, n = 21. Data are means ± standard deviation (SD). (C) Intensity of staining (left panel) or percentage of tumor cells expressing IL-10RA (n = 92) or IL-10RB (n = 89) (right panel), as determined by immunohistochemistry of a TMA of FFPE pediatric ALK⁺ ALCL patient samples. Data are presented as a violin plot with the means indicated. (D) Fold change in IL-10, IL-10RA, and IL-10RB mRNA expression levels in the indicated ALCL cell lines transduced with a doxycycline-dependent ALK shRNA. Doxycycline-induced cells were compared with noninduced cells and were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Data are means ± SD (n = 3). (E) Fold change in IL-10, IL-10RA, and IL-10RB mRNA expression levels in crizotinib-treated (300 nM for 6 hours) ALCL cell lines normalized to GAPDH and relative DMSO control. Data are means ± SD (n = 3). *P < .05. **P < .01, ***P < .001, Welch 2-sample t test.